Interferon-gamma v onkologii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the data on the immunomodulating effect of interferon-y in clinical and experimental settings, and clinical data on the use and effectiveness of the domestic preparation of recombinant interferon-y - Ingaron. Studies have demonstrated that Ingaron has significant immunomodulating activity in the treatment of cancer patients with melanoma, cervical cancer and breast cancer. The most interesting is the effect of Ingaron on natural killer cells. Regardless of the number of these cells, Ingaron increases their cytotoxic potency relative to tumor cells. Ingaron can play an important role in enhancing the effectiveness of the treatment of cancer patients.

Full Text

Restricted Access

References

  1. Хаитов Р.М., Пинегин Б.В. Современные иммуномодуляторы. Классификация. Механизмы действия // Аллергия, астма и клиническая иммунология 2000. №1. С. 9-16.
  2. Кадагидзе З.Г. Современные подходы к иммунотерапии опухолей // Новости прикладной иммунологии 2001. № 5. С. 12-14.
  3. Кадагидзе З.Г. Современные подходы к биотерапии опухолей // Аллергология и иммунология 2003. Т. 4. № 2. С. 6.
  4. Ikeda H, et al. The role of IFN gamma:in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13,95-109.
  5. Schroder K, et al. Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukocyte Biology 2004;75:163-89.
  6. Propper DJ, et al. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clinical Cancer Res 2003; 9:84-92.
  7. Wall L, et al. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clinical Cancer Res, 2003;9:2487-96.
  8. Chawla-Sarkar M, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8:237-49.
  9. Qin Z, et al. A critical requirement of interferon gamma-mediated angiosrtasis for tumor rejection by CD8+ T cells. Cancer Res 2003;63:4095-100.
  10. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005;17:180-86.
  11. Saidi RF, et al. AACR Meeting Abstracts 2006;4:1159.
  12. Славина Е.Г., Черткова А.И., Короткова О.В. и др. Модуляция интерфероном-γ цитотоксичности и индукции апоптоза доксорубицином и 5-фторурацилом // Иммунология 2005. Т. 26. № 1. С. 16-19.
  13. Otto U, Schneider A, Denkhaus H, et al. Treatment of metastatic kidney cancer with recombinant alpha-2 or gamma interferon. Results of 2 clinical phase II and III studies. Onkologie 1988;11(4):185-91.
  14. Weiner LM, Steplewski Z, Koprowski H, et al. Biologic effects of y-interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma. Hybridoma 1986;5(Suppl. 1):65-77.
  15. Aulitzky W, Gastl G, Aulitzky WE, et al. Interferon-y for the treatment of metastatic renal cancer: dose-dependent stimulation and down-regulation of y-2 microglobulin and neopterin responses. Immunobiology 1987;176:85-95.
  16. Talmadge JE, Black PL, Tribble H, et al. Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rM IFN-y, and rH IL-2. Drugs Exp Clin Res, 1987; 13:327-37.
  17. Maluish AE, Urba WJ, Longo, et al. The determination of an immunologically active dose of interferon-γ in patients with melanoma. J Clin Oncol 1988;6:434-45.
  18. Saiki I, Murata J, Saito S, et al. Effect of systemic administration of mouse recombinant interferon-y on the lung tumor metastases in mice. Mol Biother 1989;1:261-67.
  19. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic isolated limb perfusion with low dose tumor necrosis factor-alpha and melphalan for bulky in transit melanoma metastases. Ann Surg Oncol 2004;11:173-77.
  20. Ellerhorst JA, Kilbourn RG, Amato RJ, et al. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. Logothetis J Urol 1994;152(3):841-45.
  21. Small EJ, Weiss GR, Malik UK, et al. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am 1998;4(3):162-67.
  22. Pujade-Lauraine E, Guastalla JP, Colombo N, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996;14:343-50.
  23. Windbichler GH, Hausmaninger HW, Stummvoll AH, et al. Interferon-gamma in the first line therapy of ovarian cancer: a randomized phase III trial. British J Cancer 2000;82: 1138-44.
  24. Абрамов М.Е., Гуторов С.Л., Славина Е.Г. и др. Химиотерапия диссеминированной меланомы кожи с включением ингарона (у-интерферона). Клиникоиммунологическое исследование // Российский биотерапевтический журнал 2009. Т. 8. № 1. С. 64-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies